{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "NK cells",
      "T cells",
      "cancer",
      "immune cells",
      "immunometabolism",
      "immunosuppression",
      "macrophages",
      "metabolites"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34079545",
  "DateCompleted": {
    "Year": "2021",
    "Month": "09",
    "Day": "29"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "09",
    "Day": "29"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "05",
        "Day": "17"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "657293",
      "10.3389/fimmu.2021.657293"
    ],
    "Journal": {
      "ISSN": "1664-3224",
      "JournalIssue": {
        "Volume": "12",
        "PubDate": {
          "Year": "2021"
        }
      },
      "Title": "Frontiers in immunology",
      "ISOAbbreviation": "Front Immunol"
    },
    "ArticleTitle": "Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance.",
    "Pagination": {
      "StartPage": "657293",
      "MedlinePgn": "657293"
    },
    "Abstract": {
      "AbstractText": [
        "Constitutive activity of the immune surveillance system detects and kills cancerous cells, although many cancers have developed strategies to avoid detection and to resist their destruction. Cancer immunotherapy entails the manipulation of components of the endogenous immune system as targeted approaches to control and destroy cancer cells. Since one of the major limitations for the antitumor activity of immune cells is the immunosuppressive tumor microenvironment (TME), boosting the immune system to overcome the inhibition provided by the TME is a critical component of oncotherapeutics. In this article, we discuss the main effects of the TME on the metabolism and function of immune cells, and review emerging strategies to potentiate immune cell metabolism to promote antitumor effects either as monotherapeutics or in combination with conventional chemotherapy to optimize cancer management."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 Traba, Sack, Waldmann and Anton."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Departamento de Biolog\u00eda Molecular, Centro de Biolog\u00eda Molecular Severo Ochoa, Consejo Superior de Investigaciones Cient\u00edficas-Universidad Aut\u00f3noma de Madrid (CSIC-UAM), Madrid, Spain."
          }
        ],
        "LastName": "Traba",
        "ForeName": "Javier",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cardiovascular Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, United States."
          }
        ],
        "LastName": "Sack",
        "ForeName": "Michael N",
        "Initials": "MN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States."
          }
        ],
        "LastName": "Waldmann",
        "ForeName": "Thomas A",
        "Initials": "TA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States."
          }
        ],
        "LastName": "Anton",
        "ForeName": "Olga M",
        "Initials": "OM"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Intramural",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Front Immunol",
    "NlmUniqueID": "101560960",
    "ISSNLinking": "1664-3224"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cytokines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adaptive Immunity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Cell Communication"
    },
    {
      "QualifierName": [
        "immunology",
        "metabolism"
      ],
      "DescriptorName": "Cell Transformation, Neoplastic"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Cytokines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Management"
    },
    {
      "QualifierName": [
        "immunology",
        "metabolism"
      ],
      "DescriptorName": "Disease Susceptibility"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Energy Metabolism"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunity, Innate"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunomodulation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunotherapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Molecular Targeted Therapy"
    },
    {
      "QualifierName": [
        "etiology",
        "metabolism",
        "pathology",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology"
      ],
      "DescriptorName": "Tumor Escape"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Tumor Microenvironment"
    }
  ],
  "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
}